Becton, Dickinson and Company (BDX) Shares Bought by Stephens Inc. AR

Stephens Inc. AR increased its position in Becton, Dickinson and Company (NYSE:BDX) by 9.8% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 11,391 shares of the medical instruments supplier’s stock after buying an additional 1,016 shares during the period. Stephens Inc. AR’s holdings in Becton, Dickinson and were worth $2,089,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. North Star Investment Management Corp. boosted its stake in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares in the last quarter. Crestwood Advisors Group LLC purchased a new position in shares of Becton, Dickinson and during the first quarter worth approximately $101,000. Parkside Financial Bank & Trust raised its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the last quarter. Financial Architects Inc raised its position in shares of Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares during the last quarter. Finally, QCI Asset Management Inc. NY raised its position in shares of Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 60 shares during the last quarter. 75.57% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company (BDX) traded down 0.81% during mid-day trading on Friday, hitting $197.69. The company had a trading volume of 989,225 shares. The company’s 50 day moving average price is $199.72 and its 200-day moving average price is $188.69. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The firm has a market capitalization of $44.99 billion, a PE ratio of 57.25 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period last year, the company posted $2.35 earnings per share. On average, analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.48%. Becton, Dickinson and’s payout ratio is 83.43%.

COPYRIGHT VIOLATION WARNING: This piece was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/stephens-inc-ar-has-2-09-million-stake-in-becton-dickinson-and-company-bdx-updated-updated-updated.html.

A number of research analysts have commented on the company. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a research report on Monday, July 17th. Cowen and Company restated a “buy” rating and issued a $230.00 price target on shares of Becton, Dickinson and in a research report on Monday, August 14th. Finally, Barclays PLC restated an “equal weight” rating and issued a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $195.79.

In related news, insider Nabil Shabshab sold 6,149 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total transaction of $1,240,622.24. Following the completion of the transaction, the insider now directly owns 15,648 shares of the company’s stock, valued at $3,157,140.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ribo Alberto Mas sold 7,463 shares of Becton, Dickinson and stock in a transaction on Monday, August 14th. The stock was sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the completion of the transaction, the executive vice president now directly owns 29,323 shares of the company’s stock, valued at $5,905,945.43. The disclosure for this sale can be found here. Insiders have sold 57,631 shares of company stock valued at $11,112,178 over the last ninety days. 1.40% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply